(Press-News.org) Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, “Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma.”
How would you summarize your study for a lay audience?
Immunotherapy has revolutionized the management of cancer, including liver malignancies. However, the benefits are limited by multiple mechanisms of treatment resistance, including the lack of dendritic cells, which have a critical role in immune activity by helping to activate and guide other immune cells to fight infections or threats. Here, we report a strategy to increase the activity of dendritic cells and improve immunotherapy for liver cancer.
What knowledge gap does your study help to fill?
Liver cancer is a disease with a poor prognosis. Despite multiple therapeutic options, including the recent emergence of immunotherapy as a first-line systemic treatment, the outcomes remain poor. Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by 2040, underscoring the urgent need for advancements in its treatment. Our previous reports have focused on the tumor microenvironment in liver cancer, including the role of CXCR4, a receptor for CXCL12, which helps weaken the immune system’s ability to fight cancer, making it easier for the tumor to grow and spread. However, CXCR4 inhibition alone has been largely ineffective across multiple cancer models, suggesting that CXCR4 targeting should be tested in combination with other strategies.
What approach did you use?
In this study, we tested a combination blockade of PD1, a protein on the surface of immune cells that can suppress the immune system’s ability to fight cancer, and CXCR4. This study tested the effect of specifically blocking CXCR4 on standard anti-PD1 immunotherapy in liver cancer models. Most previous studies and clinical trials tested AMD3100, a small-molecule antagonist of CXCR4, which has a short half-life and a complex mechanism of action. We reasoned that using antibodies with a long half-life and specificity would help elucidate the relationship between CXCL12/CXCR4 signaling and the liver cancer microenvironment, reduce off-target effects, and improve effectiveness.
What did you find?
We discovered the potential of anti-CXCR4 to reprogram the immunologically “cold” microenvironment of liver cancer to an immunologically “hot” one because of its effects on dendritic cells and the benefits when combining them with anti-PD1, a current standard therapy for patients with liver cancer.
What are the implications?
Our study demonstrates that combining anti-CXCR4 and anti-PD1 is more effective than anti-PD1 alone in mouse models of liver cancer and that the increased dendritic cell activity contributes to the effectiveness of this combination therapy. This effect is associated with increased infiltration and activation of cytotoxic T lymphocytes and prolonged survival. These new insights into the role of CXCR4 in dendritic cells may help improve the therapeutic efficiency of standard immunotherapy for liver cancers, in which dendritic cells are scarce.
What are the next steps?
A phase I clinical trial led by Ilyas Sahin, MD, is currently being planned at Mass General Brigham to explore the clinical potential of this promising combination therapy and address the critical need for more effective treatments in liver cancer.
Authorship: In addition to Duda, Mass General Brigham authors include Satoru Morita, Pin-Ji Lei, Kohei Shigeta, Tomofumi Ando, Tatsuya Kobayashi, Hiroto Kikuchi, Aya Matsui and Peigen Huang.
Paper cited: Morita S et al. “Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma.” Cancer Immunology Research DOI: 10.1158/2326-6066.CIR-24-0324
Funding: This study was supported by Bristol Myers Squibb through a sponsored research agreement; Bristol Myers Squibb provided the murine antibodies for the treatment and financial research support for the preclinical studies. This work was supported by National Institute of Health and Department of Defense grants to Duda, postdoctoral fellowships from the Japan Society for the Promotion of Science (JSPS), Takeda Science Foundation, MGH Fund for Medical Discovery Fundamental Research, and Uehara Memorial Foundation.
Disclosures: Duda reports research grants from Bayer, Surface Oncology, and Exelixis outside the published work. No disclosures were reported by the other authors.
END
Research Spotlight: Improving liver cancer outcomes through enhanced immunotherapy
2024-12-13
ELSE PRESS RELEASES FROM THIS DATE:
Crowdsourcing hope: Book on community building shows impact of local action
2024-12-13
UNIVERSITY PARK, Pa. — Dark-humored memes — like “This is fine,” featuring a dog wearing a bowler hat in a room on fire — tend to dominate social media during times when the world appears to be falling apart. But what bothers people most can spur action and change, especially on the local level, according to Lisa Silvestri, associate teaching professor of communication arts and sciences at Penn State.
Silvestri shifted her research focus to peace- and community building after studying ...
Creating a global map of different physics laboratory classes
2024-12-13
Physics lab courses are vital to science education, providing hands-on experience and technical skills that lectures can’t offer. Yet, it’s challenging for those in Physics Education Research (PER) to compare course to course, especially since these courses vary wildly worldwide.
To better understand these differences, JILA Fellow and University of Colorado Boulder physics professor Heather Lewandowski and a group of international collaborators are working towards creating a global taxonomy, a classification system that could create a more equitable way to compare these courses. Their findings were recently ...
Astrophysicists capture astonishing images of gamma-ray flare from supermassive black hole M87
2024-12-13
Key takeaways
The galaxy M87, located in the Virgo constellation, provided the first-ever photo of a black hole in 2019, when the Event Horizon Telescope captured an image of the supermassive black hole at the galaxy’s center.
An international research team including UCLA has observed a teraelectronvolt gamma-ray flare seven orders of magnitude — tens of millions of times — larger than the event horizon, or surface of the black hole itself.
A flare of this intensity — which has not been observed in over a decade — can offer crucial insights ...
UCF named co-lead on multi-million dollar department of defense grant for STEM education
2024-12-13
The Alliance of Hispanic-Serving Research Universities (HSRU) will lead a project to increase the number of doctoral graduates in technical fields from its 22 institutions from across the nation. The initiative is supported by a new $9.3 million grant from the U.S. Department of Defense (DOD). UCF’s portion of the funding totals approximately $4.8 million.
The effort, titled Hispanic Serving Research Institutions Research and STEM Education (HSI-RSE) Project, is co-led by UCF and the University of Texas at El Paso (UTEP).
The project aims to address the critical need for high-quality ...
Multinational enterprises are failing the world’s sustainability goals
2024-12-13
Multinational enterprises (MNEs) are not just falling short of global sustainability targets but are actively contributing to the very problems they claim to address, according to a new study from the University of Surrey. This study argues that there is an urgent need for MNEs to reassess their innovation strategies to align with the United Nations Sustainable Development Goals (SDGs).
The research team found that many MNEs are prioritising profit over sustainable practices. The study highlights how MNEs often adopt superficial compliance measures rather than engaging in meaningful, sustainable innovations by analysing case studies from various countries, including both advanced ...
Unlocking the potential to better target cancer with immunotherapy
2024-12-13
Australian-led research is unlocking new ways for immunotherapy to better target cancer.
Cancer immunotherapy has revolutionised treatment for patients, whereby the body’s own immune system is harnessed to destroy cancer cells.
Typically, several molecules restrain the ability of T cells to target cancer cells and developing approaches to limit this restraining effect can lead to improved effectiveness of cancer immunotherapy.
Research published in Science Immunology has determined the structure of how an inhibitory molecule, LAG3, interacts with its main ligand and provides a new targeted approach to ...
A new twist: the molecular machines that loop our chromosomes also twist DNA
2024-12-13
A new twist: the molecular machines that loop our chromosomes also twist DNA
Scientists from the Kavli Institute of Delft University of Technology and the IMP Vienna Biocenter discovered a new property of the molecular motors that shape our chromosomes. While six years ago they found that these so-called SMC motor proteins make long loops in our DNA, they now discovered that these motors also put significant twists into the loops that they form. These findings help us better understand the structure and function of our chromosomes. They also provide insight into how disruption of twisted DNA looping can affect health—for instance, in developmental ...
New device produces critical fertilizer ingredient from thin air, cutting carbon emissions
2024-12-13
The air around us contains a powerful solution for making agriculture more sustainable. Researchers at Stanford University and King Fahd University of Petroleum and Minerals in Saudi Arabia have developed a prototype device that can produce ammonia – a key fertilizer ingredient – using wind energy to draw air through a mesh. The approach they developed, if perfected, might eliminate the need for a century-old method that produces ammonia by combining nitrogen and hydrogen at high pressures and temperatures. The older method consumes 2% of global energy and contributes 1% of annual carbon dioxide emissions from its ...
Buried landforms reveal North Sea’s ancient glacial past
2024-12-13
An international team of researchers, including a glaciologist at Newcastle University, UK, has discovered remarkably well-preserved glacial landforms buried almost 1 km beneath the North Sea.
The team used sound wave, known as seismic, data to reveal Ice Age landforms buried beneath almost 1 km of mud in the North Sea. The results, reported in the journal Science Advances, suggest that the landforms were produced about 1 million years ago, when an ice sheet centred over Norway extended towards the British Isles.
This is important because the timing of this ice advance corresponds to a period of global cooling called the Mid-Pleistocene Transition.
Glacial ...
Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer
2024-12-13
About The Study: Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab, an anti–PD-1 antibody, to neoadjuvant chemotherapy significantly improved pathological complete response.
Corresponding Authors: To contact the corresponding authors, email Zhi-Ming Shao, MD (zhiminshao@fudan.edu.cn) and Lei Fan, MD (teddyfl@163.com).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.23560)
Editor’s Note: Please see the article for additional information, including ...